24.02.2016 • News

GFBiochemicals Buys Segetis Levulinic Acid Assets

GFBiochemicals, an Italian producer of levulinic acid, has purchased the assets and intellectual property of Segetis, a US-based producer of levulinic acid derivatives, for an undisclosed sum.

The acquisition, which GFBiochemicals described as “transformational,” adds the technology for converting levulinic acid into bio-based intermediates and specialty chemicals used in a wide range of consumer products. Applications include flavors and fragrances, cosmetics, plasticizers, household and industrial cleaners, bioplastics and coatings, and agrochemicals, among others.

 It also gives GFBiochemicals a direct presence in the US market where the company plans to open offices as GFBiochemicals Americas.

Segetis, which has a pilot-scale facility in Golden Valley, Minnesota, holds more than 50 patents and has more than 200 patent applications pending worldwide. GFBiochemicals has a commercial-scale levulinic acid plant in Caserta, Italy, based on a range of biomass feedstocks, including cellulosics.

Marcel van Berkel , chief commercial officer of GFBiochemicals, said the company will continue on its development path based on organic growth and the creation of high-value partnerships with major companies, as well as the potential for further acquisitions of levulinic acid’s derivative technologies and applications.

Segetis emerged in the late 2000s as one of the first wave of companies targeting renewable chemicals.  It raised nearly $40 million in financing as it developed a portfolio of applications for renewable levulinic acid.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.